Cleared Traditional

ILO MADE IN ITALY (K943296) - FDA 510(k) Clearance

Also marketed or referenced as:
GARBO HAND FINISHED ITALY

Class I Ophthalmic device.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 1994
Decision
68d
Days
Class 1
Risk

K943296 is an FDA 510(k) clearance for the ILO MADE IN ITALY. Classified as Sunglasses (non-prescription Including Photosensitive) (product code HQY), Class I - General Controls.

Submitted by Ilo Industria Lombarda Ottica Srl (Lodi, Lo, IT). The FDA issued a Cleared decision on September 14, 1994 after a review of 68 days - a notably fast clearance cycle.

This device falls under the Ophthalmic FDA review panel, regulated under 21 CFR 886.5850 - the FDA ophthalmic device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Ilo Industria Lombarda Ottica Srl devices

Submission Details

510(k) Number K943296 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 08, 1994
Decision Date September 14, 1994
Days to Decision 68 days
Submission Type Traditional
Review Panel Ophthalmic (OP)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
42d faster than avg
Panel avg: 110d · This submission: 68d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code HQY Sunglasses (non-prescription Including Photosensitive)
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 886.5850
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.